Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

Researchers compare the convalescent humoral and cellular immune responses between children and adults infected with SARS-CoV-2.

28 Dec 2021

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

The Omicron spike is relatively poorly cleaved and impaired in mediating cell-cell fusion and syncytia formation, contrary to predictions.

28 Dec 2021

Cryo-EM of Omicron variant reveals antibody evasion by spike-ACE2 complex

Researchers compare the obtained binding affinities to wild-type and Delta spike proteins to determine the impact of Omicron mutations.

23 Dec 2021

Exploring the Mediterranean diet as a potential strategy against SARS-CoV-2

A study found that the Mediterranean diet, when combined with non-smoking and regular physical activity, can lower susceptibility to SARS-CoV-2.

22 Dec 2021

Importance of pneumococcal vaccination during the COVID-19 pandemic

A new study discusses the necessity and role of pneumococcal immunization in strengthening the global health system amid the current COVID-19 pandemic.

22 Dec 2021

Estimating vaccine efficacy against COVID-like illness from omicron and other COVID-19 variants

A new study combines real-time syndromic surveillance data from daily cross-sectional surveys with a COVID-like illness (CLI) prevalence-based vaccine efficacy estimator to better explain the early onset of the omicron variant.

21 Dec 2021

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

A new study expands the understanding of the impact of receiving a prophylactic monoclonal antibody infusion, as well as other variables, on the endogenous immune response to complete COVID-19 immunization.

20 Dec 2021

Long-term characteristics of long-COVID following hospitalization

A new study demonstrates the urgent need for healthcare services to support this huge and quickly growing patient population, which has a significant burden of symptoms, lower exercise ability, and significant reductions in health-related quality of life after one year.

17 Dec 2021

Study suggests convalescent plasma appears safe but does not prevent SARS-CoV-2 infection

A new study assesses the safety and efficacy of SARS-CoV-2 convalescent plasma containing high titers of anti-SARS-CoV-2 antibodies as PEP.

16 Dec 2021

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

A new study found that the Omicron S protein evades antibodies with a 44-fold higher efficiency than the Delta variant's spike, rendering therapeutic antibodies ineffective and likely negatively impacting antibody protection induced by infection or double vaccination.

16 Dec 2021